Slide 1: Q1 2025 Earnings Call
Q1 2025 EARNINGS CALL OFER HAVIV | PRESIDENT & CEO May 21, 2025
Slide 2: Forward-looking statements
This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the “Company”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are co
Slide 3: Agenda
Earnings Call Q1 2025 AGENDA Financial & Business Highlights Evogene Overview Subsidiaries’ Overview Q&A 3 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 4: CEO Update: Financial Highlights
4 4 CEO UPDATE Financial Highlights: In the first quarter of 2025, total revenues were ~$2.4 million, compared to ~$4.2 million in the first quarter of 2024. The first quarter 2024 revenues included license fee payments totaling $3.5 million - $2.5 million from Lavie Bio’s license fee under its coll
Slide 5: CEO Update: Business Highlights Q1 2025 to date
5 5 CEO UPDATE Business Highlights Q1 2025 to date: Evogene ChemPass-AI for Pharma: Refining ChemPass-AI’s value proposition for the pharmaceutical and biotech industries: designing novel compounds that are both highly potent and meet multiple critical development criteria. Considerable progress in
Slide 6: Business Highlights Q1 2025 to date
Business Highlights Q1 2025 to date: Casterra Delivery of ~250 tons of castor seeds to partner in Africa — surpassing the ~215 tons delivered in entire 2024. Strengthening sales team in Brazil and initial execution of a new marketing and sales strategy. Castor farming POC trials for grain (NOT seed)
Slide 7: Agenda
Earnings Call Q1 2025 AGENDA Financial & Business Highlights Evogene Overview Subsidiaries’ Overview Q&A 7 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 8: Our Vision and Mission
OUR VISION PIONEER GROUNDBREAKING LIFE-SCIENCE PRODUCTS ROOTED IN MICROBES, SMALL MOLECULES, AND GENOMICS DECODING BIOLOGY 8 OUR MISSION WE MERGE LIFE-SCIENCE WITH BIG DATA AND CUTTING-EDGE AI TECHNOLOGIES TO EFFECTIVELY DISCOVER AND OPTIMIZE BREAKTHROUGH LIFE-SCIENCE BASED PRODUCTS
Slide 9: Discovery & Optimization
DISCOVERY & OPTIMIZATION WE DIRECT AND ACCELERATE LIFE-SCIENCE PRODUCT through 3 dedicated AI tech-engines MICROBES GENETIC ELEMENTS SMALL MOLECULES The Result: Promising candidates addressing multiple development challenges towards successful life-science-based products. PROBABILITY OF SUCCESS TIME
Slide 10: Business Strategy
10 BUSINESS STRATEGY Capture the value of our AI tech-engines through diverse collaborative partnerships to accelerate life-science product development Partnering with experts in specific fields complements our technology, enabling groundbreaking innovations and financial gains for Evogene. EVOGENE
Slide 11: Licensing & Collaboration | Current Status
11 LICENSING & COLLABORATION | CURRENT STATUS Aquaculture Crustacean gene editing Food-tech Protein production in Plants for food-tech Crop protection Weed Control Disease Control Insect Control Improved traits - canola Microbials for crops Therapeutic microbials SMALL MOLECULES GENETIC ELEMENTS MIC
Slide 12: Looking into 2025-2026
12 LOOKING INTO 2025-2026 Evogene Focus on enhancing ChemPass AI tech-engine’s competitive advantage for the pharma market segment (ex. – building foundation model with Google Cloud). Engage in collaborations with bio-tech and academia for small-molecule drug discovery, utilizing ChemPass AI. Contin
Slide 13: Value Proposition
13 13 Value Proposition Our solution enables pharmaceutical and biotech companies to create breakthrough therapies while achieving strong and comprehensive intellectual property protection. We address a critical bottleneck in small-molecule drug development- the discovery and design of highly potent
Slide 14: ChemPass AI For Drug Development
14 14 ChemPass AI For Drug Development At the core of our approach is ChemPass AI — a proprietary computational platform powered by our in-house developed generative AI technology. Purpose-built to explore uncharted chemical space, ChemPass AI delivers finely optimized molecules that meet complex pr
Slide 15: Drug Discovery & Development Pipeline
15 15 TARGET SELECTION Identifying disease-relevant proteins or pathways as viable therapeutic targets DISCOVERY Identifying and refining compounds through screening and optimization to create potent, selective, and safe drug candidates. PRECLINICAL DEVELOPMENT Rigorous in vitro and in vivo studies
Slide 16: Evogene's Offering: Drug Discovery & Development Pipeline
16 16 Evogene’s Offering Drug Discovery & Development Pipeline HIT-TO-LEAD HIT SCREENING LEAD OPTIMIZATION TARGET SELECTION DISCOVERY . PRECLINICAL DEVELOPMENT CLINICAL STUDIES
Slide 17: Evogene's Drug Discovery Platform
17 17 Evogene’s Drug Discovery Platform HIT SCREENING PointHit and DeepDock Utilizing Deep learning to enhance rapid screening in large databases HIT-TO-LEAD ActiveSearch DMTA coupled with upgraded analogue search using propriety algorithms LEAD OPTIMIZATION ChemPassGPT De-novo design with in-house
Slide 18: Proprietary foundation model trained on ~38B molecules
18 18 Evogene’s proprietary foundation model, integrated into ChemPass-GPT, trained on ~38B molecules, dramatically expands accessible chemical space to: Generate novel and valid molecules Improve efficacy predictions Optimize across multiple required parameters our first in class FOUNDATION MODEL T
Slide 19: ICL to Acquire the Activity of Lavie Bio
19 ICL to Acquire the Activity of Evogene’s subsidiary, Lavie Bio Focus on creating exit events for Evogene with respect to part of our subsidiaries.
Slide 20: Agenda
Earnings Call Q1 2025 AGENDA Financial & Business Highlights Evogene Overview Subsidiaries’ Overview Q&A 20 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 21: Lavie Bio and the ICL acquisition
21 Lavie Bio, a global leader in developing next generation ag-biological products, leveraging MicroBoost AI tech-engine On April 21, 2025, Evogene announced the acquisition of most of the activity of Lavie Bio by ICL, for US$15.25 million. As part of the transaction ICL's SAFE investment in Lavie B
Slide 22: Casterra: castor bean farming and 2025 targets
22 Casterra focuses on developing integrated solutions for large-scale castor bean farming, utilizing GeneRator AI tech-engine Powered by Main targets for 2025 Increase castor seeds revenue in Africa; initial sales in Brazil and additional territories. Initiate POC trials for grain (NOT seed) farmin
Slide 23: AgPlenus: crop protection and 2025 targets
AgPlenus specializes in developing novel and sustainable crop protection products, utilizing Evogene’s ChemPass AI tech-engine Powered by 23 Main targets for 2025 Achieve 2nd milestone in Corteva collaboration agreement. Continue execution of Bayer herbicide collaboration according to workplan. Disc
Slide 24: Biomica: microbiome therapeutics and 2025 targets
24 Biomica specializes in developing microbiome-based therapeutics for human health, utilizing Evogene's MicroBoost AI tech-engine Powered by Main targets for 2025 Complete Phase 1 study in oncology program; obtain full results and additional supporting clinical data. Submit IND application to the U
Slide 25: Agenda
Earnings Call Q1 2025 AGENDA Financial & Business Highlights Evogene Overview Subsidiaries’ Overview Q&A 25 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 26: CFO Update: Assets
CFO UPDATE March 31, December 31, 2025 2024 Unaudited ASSETS CURRENT ASSETS: Cash and cash equivalents $ 7,495 $ 15,301 ‘Short-term bank deposits 2,354 10 Trade receivables 2,640 1,091 Other receivables and prepaid expenses 651 2,064 Deferred expenses related to issuance of warrants 1,209 1,304 Inve
Slide 27: CFO Update: Liabilities and Equity
MEECFO UPDATE a Unaudited LIABILITIES AND EQUITY CURRENT LIABILITIES: Trade payables s 592 s 1228 Employees and payroll accruals, 1,622 1,869 Lease liabilities 670 589 Liabilities in respect of government grants 353, 323 Deferred revemues and other advances 209 360 ‘Warrants and pre-funded warrants
Slide 28: CFO Update: Evogene Financial Performance Q1 2025
CFO UPDATE Evogene Financial Performance Q1 2025 28
Slide 29: Agenda
Earnings Call Q1 2025 AGENDA Financial & Business Highlights Evogene Overview Subsidiaries’ Overview Q&A 29 CEO Update / By Ofer Haviv CFO Update / By Yaron Eldad
Slide 30: Thank You
} THANK YOU 5)